Panbela Therapeutics Inc. Common Stock
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was founded in 2011 and is based in Waconia, Minnesota.
PBLA Overview
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$2.1700 |
Previous Close Volume |
489590 |
Latest News
-
Panbela Provides Business Update and Reports Q3 2024 Financial Results
14 Nov 2024 17:02:27
https://panbela.com/wp-content/uploads/2024/11/PBLA-PR-Q4-Earnings-Release_final.pdf
-
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
31 Oct 2024 10:34:04
https://panbela.com/wp-content/uploads/2024/10/PBLA-FINAL-PR-Q3-Earn-Date.pdf
-
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
24 Sep 2024 08:18:43
https://panbela.com/wp-content/uploads/2024/09/PBLA-PR-Moffitt-Phase-1-First-Patient_FINAL.pdf
-
Panbela Provides Business Update and Reports Q2 2024 Financial Results
13 Aug 2024 16:32:44
https://panbela.com/wp-content/uploads/2024/08/PBLA-Final-PR-Q2-2024.pdf
-
Panbela to Host Q2 2024 Earnings Conference Call on 8/13/24
30 Jul 2024 17:18:05
https://panbela.com/wp-content/uploads/2024/07/PBLA-PR-Q2-2024-Earnings-Date.pdf
-
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial
24 Jun 2024 10:03:10
https://panbela.com/wp-content/uploads/2024/06/PBLA-PR-3rd-DSMB-FINAL.pdf
-
Panbela Announces Oral Presentation at Digestive Disease Week (DDW)
10 Jun 2024 08:33:20
https://panbela.com/wp-content/uploads/2024/06/PBLA-PR-DDW-Oral-Presentation.pdf
-
Panbela Provides Business Update and Reports Q1 2024 Financial Results
15 May 2024 17:18:00
https://panbela.com/wp-content/uploads/2024/05/04-PBLA-PR-Q1-2024.pdf
-
Panbela Announces Issuance of New US & Canada Patent for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
06 May 2024 09:18:21
https://panbela.com/wp-content/uploads/2024/05/PBLA-Fynpovi-Canadian-and-US-Continuation-Patent.pdf
-
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
01 May 2024 16:18:32
https://panbela.com/wp-content/uploads/2024/04/PBLA-PR-Q1-24-Earnings-Date.pdf
-
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week (DDW)
30 Apr 2024 08:19:00
https://panbela.com/wp-content/uploads/2024/04/PBLA-PR-DDW-Acceptance.pdf
-
Panbela Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
22 Apr 2024 10:03:32
https://panbela.com/wp-content/uploads/2024/04/PBLA-PR-updates-interim-analysis-timeline.pdf
-
Panbela Announces Poster Presentation at American Association for Cancer Research
18 Apr 2024 09:33:45
https://panbela.com/wp-content/uploads/2024/04/PBLA-PR-AACR-Presentation.pdf
-
Panbela Announces Transfer to OTCQB Market
16 Apr 2024 18:19:18
https://panbela.com/wp-content/uploads/2024/04/PBLA-PR-OTCQB-April24.pdf
-
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
26 Mar 2024 16:18:54
https://panbela.com/wp-content/uploads/2024/03/PBLA-PR-Earnings-FYE-2023-12-31-final.pdf
-
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on 3/26/24
12 Mar 2024 17:18:54
https://panbela.com/wp-content/uploads/2024/03/PBLA-FINAL-PR-Q4-2023-Earnings-Date.pdf
-
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
15 Feb 2024 09:33:51
https://panbela.com/wp-content/uploads/2024/02/PBLA-PR-Nasdaq-Compliance.pdf
-
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
30 Jan 2024 11:19:05
https://panbela.com/wp-content/uploads/2024/01/PBLA-PR-AACR-Acceptance-FINAL.pdf
-
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
29 Jan 2024 11:48:56
https://panbela.com/wp-content/uploads/2024/01/PBLA-PR-Offering-2024-01-29.pdf
-
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer
25 Jan 2024 08:34:28
https://panbela.com/wp-content/uploads/2024/01/PBLA-draft-PR-50-Percent-Enrollment.pdf
- Panbela Announces Publication of Clinical Data: A New Approaches to Neuroblastoma Therapy Trial 18 Jan 2024 10:33:57
-
Panbela Announces 1-for-20 Reverse Stock Split Effective 1/18/24
16 Jan 2024 10:03:52
https://panbela.com/wp-content/uploads/2024/01/PBLA-PR-Reverse-Split-Jan-18-2024.pdf
-
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
29 Nov 2023 09:30:21
https://panbela.com/wp-content/uploads/2023/11/PBLA-PR-ASPIRE-DSMB-29NOV2023-.pdf
-
Panbela Announces Validation of European Patent for Claims of a Novel Process for the Production of SBP-101
31 Oct 2023 09:15:21
https://panbela.com/wp-content/uploads/2023/10/PBLA-SBP101-EP-Country-Validations_Syngene.pdf
-
Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer
24 Jul 2023 09:20:13
https://panbela.com/wp-content/uploads/2023/07/PBLA-PR-Aspire-UK-Germany.pdf